文献速递白血病

二代测序识别低危急性髓系白血病复发相关基因突变

Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients.
PubMed 文献 · Br J Haematol · 2020-03-02

该研究采用二代测序评估166例低危急性髓系白血病患者的突变谱,包括30例核心结合因子AML、33例NPM1-AML、4例双CEBPα-AML和101例急性早幼粒细胞白血病。

要点

  • NPM1-AML中剪接基因突变是RFS和OS的独立不良因素。
  • CBF-AML中RAS通路和黏连蛋白基因突变分别独立预测RFS和OS不良。
  • 低危APL中NRAS突变与5年RFS缩短强相关(25% vs. 100%)。

核心结论

  • 基因突变可识别传统低危AML中预后不良的患者,有助于更好的风险分层和治疗决策。

研究设计与样本

  • 研究采用二代测序评估166例低危AML患者的突变谱,包括30例CBF-AML、33例NPM1-AML、4例双CEBPα-AML和101例APL。

主要发现

  • NPM1-AML中DNA甲基化基因突变频率达79%,但无预后影响;剪接基因突变是RFS和OS的独立不良因素。
  • CBF-AML中RAS通路突变是RFS的独立不良因素,黏连蛋白基因突变是OS的独立不良因素。

临床怎么用

  • 对传统低危AML患者进行二代测序突变检测,可识别预后不良亚群并指导风险分层和治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recommended genetic categorization of acute myeloid leukaemias (AML) includes a favourable-risk category, but not all these patients have good prognosis. Here, we used next-generation sequencing to evaluate the mutational profile of 166 low-risk AML patients: 30 core-binding factor (CBF)-AMLs, 33 nucleophosmin (NPM1)-AMLs, 4 biCEBPα-AMLs and 101 acute promyelocytic leukaemias (APLs). Functional categories of mutated genes differed among subgroups. NPM1-AMLs showed frequent variations in DNA-methylation genes (DNMT3A, TET2, IDH1/2) (79%), although without prognostic impact. Within this group, splicing-gene mutations were an independent factor for relapse-free (RFS) and overall survival (OS). In CBF-AML, poor independent factors for RFS and OS were mutations in RAS pathway and cohesin genes, respectively. In APL, the mutational profile differed according to the risk groups. High-risk APLs showed a high mutation rate in cell-signalling genes (P = 0·002), highlighting an increased incidence of FLT3 internal tandem duplication (ITD) (65%, P < 0·0001). Remarkably, in low-risk APLs (n = 28), NRAS mutations were strongly correlated with a shorter five-year RFS (25% vs. 100%, P < 0·0001). Overall, a high number of mutations (≥3) was the worst prognostic factor RFS (HR = 2·6, P = 0·003). These results suggest that gene mutations may identify conventional low-risk AML patients with poor prognosis and might be useful for better risk stratification and treatment decisions.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Prieto-Conde MI, Jiménez C, García-Álvarez M, et al. Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients. Br J Haematol. 2020. PMID: 32124426. doi:10.1111/bjh.16420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。